



Australian Government

Department of Health
Therapeutic Goods Administration

Advisory Committee on Vaccines

Meeting Statement 19 - Wednesday 3 February 2021

Section A: Submissions for registration

The committee provided advice on one application to register a new vaccine.

Further details of the ACV discussion and advice associated with these pre-market items may be released within the Australian Public Assessment Report (AusPAR). Please note that there is a delay between when an application is considered by the ACV and the publication of the AusPAR. To browse all AusPARs see [AusPAR search](#).

Section B: Safety

The committee provided further advice and endorsed the COVID-19 Vaccine Pharmacovigilance Plan, which had been amended following the ACV meeting 16 held 30 September 2020.

Further information

For further information on the ACV, please visit [Advisory Committee on Vaccines](#) or contact the ACV by email ACV@health.gov.au.